Issue Archive

We feature a series of authoritative reviews on a collection of rare systemic hematologic disorders that are frequently difficult to recognize, diagnose, and treat. The series highlights new genomic and proteomic insights that inform our understanding of their pathophysiology and treatment.

Recurrent ipsilateral deep vein thrombosis has major clinical ramifications, but is often difficult to distinguish from residual clot by ultrasound. van Dam et al demonstrated that magnetic resonance direct thrombus imaging can accurately distinguish the two, with a low risk of venous thromboembolism recurrence after a negative study.

In this month’s CME article, Vercellino and colleagues report results of a secondary analysis of diffuse large B-cell lymphoma patients in the REMARC trial who had baseline positron emission tomography scans, thereby demonstrating that metabolic tumor volume combined with performance status allowed risk stratification of patients before treatment and predicted survival independent of response to chemoimmunotherapy.

The Platelet Transfusion in Cerebral Hemorrhage (PATCH) trial, a trial of platelet transfusion in patients on antiplatelet agents with cerebral hemorrhage, suggested that platelets worsened outcomes. Reanalysis of the data by the investigators revealed that despite randomization, some, if not all, of the adverse effects of platelets reflected worse baseline hemorrhage in patients in the platelet arm.

We feature a series of authoritative reviews on a collection of rare systemic hematologic disorders that are frequently difficult to recognize, diagnose, and treat. The series highlights new genomic and proteomic insights that inform our understanding of their pathophysiology and treatment.

We feature a series of authoritative reviews on a collection of rare systemic hematologic disorders that are frequently difficult to recognize, diagnose, and treat. The series highlights new genomic and proteomic insights that inform our understanding of their pathophysiology and treatment.

We feature a series of authoritative reviews on a collection of rare systemic hematologic disorders that are frequently difficult to recognize, diagnose, and treat. The series highlights new genomic and proteomic insights that inform our understanding of their pathophysiology and treatment.

We feature a series of authoritative reviews on a collection of rare systemic hematologic disorders that are frequently difficult to recognize, diagnose, and treat. The series highlights new genomic and proteomic insights that inform our understanding of their pathophysiology and treatment.

We feature a series of authoritative reviews on a collection of rare systemic hematologic disorders that are frequently difficult to recognize, diagnose, and treat. The series highlights new genomic and proteomic insights that inform our understanding of their pathophysiology and treatment.

We feature a series of authoritative reviews on a collection of rare systemic hematologic disorders that are frequently difficult to recognize, diagnose, and treat. The series highlights new genomic and proteomic insights that inform our understanding of their pathophysiology and treatment.

It has been suggested that modulation of natural killer (NK) cell activity has an impact on relapse and survival in stem cell transplantation for myeloid malignancy. In a retrospective study of over 2200 patients, Schetelig et al demonstrated that modeling donor selection based on advantageous KIR and KIR ligand expression does not predict relapse or survival, thereby confirming that the mechanism of NK-cell mediated alloreactivity is more complex than postulated.

In this month’s CME article, Vercellino and colleagues report results of a secondary analysis of diffuse large B-cell lymphoma patients in the REMARC trial who had baseline positron emission tomography scans, thereby demonstrating that metabolic tumor volume combined with performance status allowed risk stratification of patients before treatment and predicted survival independent of response to chemoimmunotherapy.